UBS analyst Alex Kramm lowered the firm’s price target on CME Group (CME) to $285 from $305 and keeps a Neutral rating on the shares. While the firm raised its estimates, Q3 is still trending lower, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group reports August ADV of 28.1M contracts
- Crypto Currents: U.S. eyes on-chain GDP data, Google plans layer-1 blockchain
- CME Group CIO sells $3.23M in common stock
- DraftKings likely to follow Flutter into prediction market, says Jefferies
- CME Group and Flutter’s FanDuel partner in new event contracts platform